NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synergetics USA, Inc. (“Synergetics” or the “Company”) (NASDAQ:SURG) for potential breaches of fiduciary duties in connection with the sale of the Company to Valeant Pharmaceuticals for approximately $166 million in a cash transaction.
The Company’s stockholders will only receive $6.50 for each share of Company common stock they own. However, the offer is virtually no premium over the 52-week high.
Click here for more information: www.faruqilaw.com/SURG. There is no cost or obligation to you.
The investigation focuses on whether Synergetics’ Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Synergetics’ shareholders.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.
If you own common stock in Synergetics and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/SURG or contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Attorney Advertising. (C) 2015 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.